Based on the bioinformatics data, TCGA data and the recent studies, we can clearly recognise that there is a large variability in the biological process of ferroptosis in different breast cancer molecular subtypes, and even some key regulatory genes, such as GPX4 and IDH2, have completely different expression statuses in different subtypes, and show opposite features in the clinical prognosis. The gene discussed is GPX4; the disease is breast cancer.